How often it happens The rates vary by trial and population: 2,3 TRIUMPH-4 (obesity with knee osteoarthritis): 8.8% on 9 mg, 20.9% on 12 mg, 0.7% on placebo TRANSCEND-T2D-1 (type 2 diabetes): 4.5% on 4 mg, 2.3% on 9 mg, 4.4% on 12 mg, 0% on placebo Phase 2 trial (Jastreboff 2023): not reported The TRIUMPH-4 numbers are markedly higher than those of TRANSCEND-T2D-1
The Dual-Pathway Model vs Single-Agent Administration The combinations pharmacological rationale mirrors the bodys natural dual-regulation of GH secretion, where both GHRH and ghrelin signals converge on pituitary somatotrophs for optimal GH output
Astaxanthin is generally safe
The animation traces its signal outward from the compound to every target it engages
Some individuals experienced dramatic improvements with lower amounts
Biochem J (2007) 403(1):13948